Vocabria (cabotegravir) vs Apretude (cabotegravir extended-release injectable suspension)
Vocabria (cabotegravir) vs Apretude (cabotegravir extended-release injectable suspension)
Vocabria (cabotegravir tablets) is an oral medication that is typically used for a short period as an introductory treatment for HIV-1 infection in combination with other antiretroviral drugs, before transitioning to a long-acting injectable regimen. Apretude (cabotegravir extended-release injectable suspension) is an injectable form of cabotegravir that is used for the long-term maintenance treatment of HIV-1 infection, administered once every 1 or 2 months after an initial oral lead-in period with Vocabria. When deciding between the two, it is important to consider the convenience and adherence preferences, as Vocabria offers the flexibility of daily oral dosing, while Apretude reduces the burden of daily medication with its long-acting injectable schedule, but requires visits to a healthcare provider for administration.
Difference between Vocabria and Apretude
Metric | Vocabria (cabotegravir) | Apretude (cabotegravir extended-release injectable suspension) |
---|---|---|
Generic name | Cabotegravir | Cabotegravir |
Indications | HIV-1 infection treatment (in combination with other antiretroviral agents) | HIV-1 pre-exposure prophylaxis (PrEP) |
Mechanism of action | Integrase inhibitor | Integrase inhibitor |
Brand names | Vocabria | Apretude |
Administrative route | Oral | Injectable |
Side effects | Headache, insomnia, fatigue, gastrointestinal issues | Injection site reactions, fever, fatigue, headache, musculoskeletal pain |
Contraindications | Hypersensitivity to cabotegravir or any of the excipients | Hypersensitivity to cabotegravir or any of the excipients |
Drug class | Integrase strand transfer inhibitor (INSTI) | Integrase strand transfer inhibitor (INSTI) |
Manufacturer | ViiV Healthcare | ViiV Healthcare |
Efficacy
Efficacy of Vocabria (Cabotegravir) for HIV/AIDS
Vocabria, with the active ingredient cabotegravir, is an antiretroviral medication used in the treatment and prevention of the human immunodeficiency virus (HIV). As an integrase strand transfer inhibitor (INSTI), cabotegravir works by preventing the virus from integrating its genetic material into the host cell's DNA, a critical step in the HIV replication cycle. This mechanism effectively reduces the viral load in the patient's body and helps maintain the function of the immune system. Clinical trials have demonstrated that Vocabria, when used in combination with other antiretroviral agents, is effective in maintaining viral suppression in individuals with HIV-1 infection.
Efficacy of Apretude (Cabotegravir Extended-Release Injectable Suspension) for HIV/AIDS
Apretude is an extended-release injectable formulation of cabotegravir designed for the prevention of HIV-1 infection as pre-exposure prophylaxis (PrEP) in at-risk populations. It is administered as an intramuscular injection once every two months following an initial loading dose. The efficacy of Apretude for HIV prevention has been established through randomized controlled trials, which have shown a significant reduction in the incidence of HIV-1 infection among individuals receiving the injectable cabotegravir compared to those receiving daily oral PrEP with emtricitabine/tenofovir disoproxil fumarate. Apretude's long-acting formulation provides an alternative for those who may have difficulty adhering to a daily oral regimen.
It is important to note that both Vocabria and Apretude are indicated for use as part of a comprehensive HIV treatment or prevention strategy, which may include other antiretroviral medications, regular monitoring of HIV viral load, and additional preventive measures. The use of these medications should be guided by healthcare professionals with expertise in managing HIV/AIDS, and patients should be counseled on the importance of adherence to the prescribed treatment or prevention regimen to ensure optimal efficacy.
While the use of Vocabria and Apretude has shown promising results in the management and prevention of HIV/AIDS, ongoing research and post-marketing surveillance continue to provide valuable information on their long-term efficacy and safety profiles. Patients and healthcare providers are encouraged to report any adverse reactions or concerns to the appropriate regulatory agencies to contribute to the body of knowledge on these medications.
Regulatory Agency Approvals
Vocabria
Apretude
Access Vocabria or Apretude today
If Vocabria or Apretude are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us